Huma

🚀 Exciting CNS Summit news! 🌐 We are thrilled to announce that Dan Vahdat, our CEO, and Dr Mert Aral, our CMO, will take the stage for two pivotal sessions this year. 🔍 Spotlight Session: Build and Deploy Medical Apps (with FDA 510k) or Research Apps in Hours Instead of Years 📅 Date: Monday, November 11th 🕐 Session Time: 1:00 – 1:50 PM ET 📍 Location: Renoir 1/2 Get ready for something special! Dan and Mert will co-present a live demo, showcasing a transformative platform that drastically cuts development time from years to hours. Our breakthrough technology enables rapid deployment and iteration of digital health applications for clinical trials, remote monitoring, and companion SaMD—all while ensuring regulatory compliance across global markets. 🎤 Panel Session: Digital Medicine Forum: Dan Vahdat (Huma) and Edward Cox (Pfizer), Moderated by Ritesh Patel (FINN Partners) 📅 Date: Wednesday, November 13th 🕚 Session Time: 11:00 AM – 12:00 PM ET 📍 Location: Picasso Ballroom In this panel, Dan and Ed will discuss how creating digital tools for patient engagement, data collection, and monitoring in clinical trials must be flexible, cost-efficient, and fast—because delays aren’t an option. They will discuss our work to utilise digital health to reduce development time from years to hours, enabling quick launches and rapid iteration of trial software. They’ll also discuss how this aligns with the latest FDA guidance on Prescription Drug Use-Related Software (PDURS), driving faster trials, cost savings, and streamlined project execution. If you’re attending the CNS Summit, don’t miss these sessions! We can’t wait to share how our innovations are shaping the future of digital health and clinical research. #CNSSummit #DigitalHealth #ClinicalTrials #PatientEngagement #RegulatoryCompliance #HumaInnovation #CNSSummit2024

🚀 Big ambitions, bold vision! Our CEO and founder, Dan Vahdat, recently joined The Venture Podcast with McKinsey & Company’s Timothy Yap, Senior Partner, to share the incredible journey behind Huma’s mission to reshape healthcare. 🏥 Growing up in a family of doctors, Dan saw firsthand how patient care often fades once they leave the hospital—leading to preventable complications. Driven by this, Dan founded Huma in 2011 with one clear purpose: to make healthcare proactive. But back then, the technology was just a dream. 💥Fast forward to today, and Huma’s AI-powered Cloud Platform, combined with wearable tech, is making that dream a reality. "We’re now at a point where real-time data can drive real-time interventions," Dan says. With regulatory approval in the US and EU, Huma’s platform is not only enabling proactive patient care but empowering other health tech companies to build on our foundation. 💡Dan’s vision? To build the world’s largest digital health company—one that redefines care across the globe, bringing everyone to a world of seamless, continuous healthcare. Catch Dan’s conversation with McKinsey’s Timothy Yap on The Venture Podcast and join us as we shape the future of healthcare! https://lnkd.in/d9jPqrSH

Huma intelligence (Hi) update: We’ve developed a model at Huma called Trans-ROM to accurately measure range-of-motion across various exercises. The Trans-ROM algorithm can deliver reliable, real-time, actionable insights for rehabilitation, physical therapy, or sports performance directly from an individual's mobile device. Our model excels in even the most challenging conditions, including when users are positioned on their side, ensuring precision in detecting occluded joints. The model has been technically validated as part of a Gait lab study. Want to explore more about this cutting-edge technology and its potential applications for your work? Reach out! #Huma #AI #MachineLearning #RangeOfMotion #HealthcareInnovation #PhysicalTherapy #Rehabilitation

Meet Huma at #HLTH2024 in Vegas! Our Head of US Kaushik Gune will attend the conference and speak during the private HLTH Inc. Think Tank in partnership with ZS. Join us to explore how Digital Health and AI can transcend traditional go-to-market strategies. Apply below to join this invite-only event : https://lnkd.in/eqNRzR2E

Huma CEO & Founder Dan Vahdat joined Tom Mackenzie of Bloomberg to share how we are accelerating the adoption of digital/AI across care and research through the Huma Cloud Platform, as well as acquisitions like eConsult, with the goal of building an end-to-end, digital-first care offering. Click below to learn more about our strategy behind the acquisition and our plans for the future: https://lnkd.in/e_nrWstB

A Huma-powered Bayer program has broken a #GuinnessWorldRecord! 🚀 In support of Aspirin, and in combination with other initiatives, our technology has powered the highest number of cardiovascular disease (CVD) screenings ever done in 12 hours as part of #WorldHeartDay. We are immensely proud to support the Bayer team in their mission to save millions of lives by breaking down barriers and enhancing accessibility, awareness, and diagnosis of CVD. Guinness World Records #CardiovascularDisease #DigitalHealth

Mark your calendars for September 25! Join us for an exclusive webinar where industry experts from Alcedis - a HUMA company, AstraZeneca, and CompuGroup Medical SE & Co. KGaA will share groundbreaking insights from the innovative InspeCKD study. The InspeCKD study analyzed over 400,000 anonymized patient records from 1,250 general practices across Germany to uncover important trends in chronic kidney disease (CKD) screening and diagnostics. Learn about the cutting-edge methods used, how real-world data was leveraged, and the strategies developed to overcome the challenges of data integration. Don’t miss this opportunity to gain valuable insights from leaders in the field and stay ahead of the curve. Our speakers: Dr. Nils Kost - Director Evidence at AstraZeneca Philipp Thiele - General Manager of CompuGroup Medical SE & Co. KGaA Frederik M. Mader - Specialist in general medicine and Professor at IU International University Dr. Hendrik Melior - Project Manager Clinical Operations at Alcedis Register here: https://lnkd.in/eCjnSb4y Read more about InspeCKD: https://lnkd.in/eH_5haQV

At Huma, we believe that AI is key to enabling personalised care at scale. Our HumaMG program uses advanced machine learning and imaging capabilities to support improved monitoring of disease progression for people with #MyastheniaGravis. On September 26, Huma's Chief Medical Officer Dr Mert Aral and Benjamin Irving, VP ML & Imaging, will be leading a webinar session hosted by the Myasthenia Gravis Foundation of America, Inc., in which they'll share more on the HumaMG app and how it uses AI to enhance the #MG care pathway. Living Better with MG: How AI Enhances Treatment and Management 📅 Date: Thursday, September 26, 12pm EST 🔗 Register here:https://lnkd.in/efa96_nJ 🔗 Learn more about HumaMG: https://lnkd.in/eekJTUxQ

Meet Huma at #ESMO2024! Dr Mert Aral, our Chief Medical Officer and Hanno Härtlein, Head of Clinical Trials at Alcedis - a HUMA company will be joining at the ESMO - European Society for Medical Oncology conference in Barcelona next week. Get in touch!

Huma is proud announce the launch of our new app in partnership with Servier Pharmaceuticals, designed to support patients diagnosed with glioma—a type of tumor affecting the brain or spinal cord. Gliomas are the most common type of primary CNS tumor, and they bring with them a range of challenges, from physical symptoms to emotional stress. Our goal is to provide patients and caregivers resources that can support them in navigating this difficult journey. Huma founder & CEO Dan Vahdat said, “Supporting people living with cancer has been a priority at Huma since day one. We are proud to be working with Servier to help glioma patients get access to critical information about their condition and monitor their disease.“ Wendy Poage, Vice President of Servier’s Patient Office, said “At Servier, our unique governance allows us to focus on patient centricity across all aspects of our organization... This app is one example of the ‘beyond the pill’ digital solutions we are working to provide to patients, caregivers, advocacy groups and others.” The app is now available for free to all patients in the United States, with plans to expand globally in the future. We believe in the power of digital technology to improve cancer care, and this app is just one of the ways we're making a difference. Read more: https://lnkd.in/erauTAHQ